# US 8,278,433 B2 · Methods and compositions for expressing negative-sense viral RNA in canine cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,433 B2
- Document ID: US8278433B2
- Status: Granted
- Kind: B2
- Application number: 12/842,854
- Filed: 2010-07-23
- Published: 2011-02-24
- Granted: 2012-10-02
- Earliest claimed: 2005-06-21
- Assignees: MedImmune, LLC
- Inventors: Gregory Duke; George Kemble; James Young; Zhaoti Wang
- Web page: https://patentgrep.com/patent/US8278433B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C12N 9/1247: {DNA-directed RNA polymerase (2.7.7.6)}
- C12N 15/85: for animal cells
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12N 2510/02: Cells for production
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.

## Claims

### Claim 1

An isolated nucleic acid comprising a canine RNA polymerase I promoter, wherein the nucleic acid comprises
a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:26 or the complement or reverse complement thereof,
wherein the polynucleotide when operably linked to cDNA encoding an influenza vRNA and introduced into a Madin-Darby canine kidney (MDCK) cell is capable of directing the expression of the influenza vRNA.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the regulatory sequence is operably linked to cDNA encoding a negative-strand viral genomic RNA or the corresponding cRNA.

### Claim 3 (depends on 2)

The isolated nucleic acid of claim 2, wherein the nucleic acid further comprises a transcription termination sequence.

### Claim 4 (depends on 3)

The isolated nucleic acid of claim 3, wherein the negative-strand viral genomic RNA is an influenza genomic RNA.

### Claim 5 (depends on 4)

An expression vector comprising the nucleic acid of claim 4.

### Claim 6 (depends on 5)

An isolated cell comprising the expression vector of claim 5.

### Claim 7 (depends on 6)

The isolated cell of claim 6, wherein the cell is a canine cell.

### Claim 8 (depends on 7)

The isolated cell of claim 7, wherein the canine cell is a kidney cell.

### Claim 9 (depends on 8)

The isolated cell of claim 8, wherein the canine kidney cell is an MDCK cell.

### Claim 10 (depends on 5)

The expression vector of claim 5, wherein the vector comprises the nucleotide sequence set forth as SEQ ID NO:29.

### Claim 11

An isolated nucleic acid comprising:
(a) a fragment comprising at least 250, or at least 350, or at least 450 contiguous nucleotides of a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:26 or the complement or reverse complement thereof, or
(b) a polynucleotide having at least 96% identity to a polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO:26 or the complement or reverse complement thereof.

### Claim 12 (depends on 11)

The isolated nucleic acid of claim 11, wherein the polynucleotide of (a) comprises the 3′ nucleotide of SEQ ID NO:26.

### Claim 13 (depends on 11)

The isolated nucleic acid of claim 11, wherein the polynucleotide of (b) comprises the 3′ nucleotide of SEQ ID NO:26.

### Claim 14 (depends on 12)

A vector comprising the nucleic acid of claim 12.

### Claim 15 (depends on 14)

An isolated cell comprising the vector of claim 14.
